-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Linuo Pharmaceutical
Shandong Keyuan Pharmaceutical Co.,Ltd. was established in 2002 and is a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ), a leading enterprise in the domestic chemical API sub‑sector. The company focuses on the R&D, production, and sales of chemical pharmaceutical preparations, has built an extensive product portfolio in chronic disease areas such as diabetes, cardiovascular disorders, and the central nervous system, and has accumulated strong R&D capabilities. In recent years, the company has adopted a development strategy of “one core, two wings, three pillars,” deepening technological R&D, implementing digital and intelligent manufacturing, and promoting cultural marketing, thereby establishing a complete industrial system that integrates APIs and formulations and seamlessly connects the entire upstream–downstream value chain, steadily expanding its competitive edge in the market.
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline